PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic ...
Credit: scPharmaceuticals. Previously, the novel furosemide delivery system was only indicated for congestion due to fluid overload in adult patients with NYHA Class II and Class III CHF. The Furoscix ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results